Drug Profile
Zagotenemab - Eli Lilly and Company
Alternative Names: LY 3303560Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 26 Oct 2021 Discontinued - Phase-I for Alzheimer's disease in Japan, United Kingdom, USA (SC), prior to October 2021 (Eli Lilly and Company pipeline, October 2021)
- 26 Oct 2021 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (IV), prior to October 2021 (Eli Lilly and Company pipeline, October 2021)
- 26 Oct 2021 Discontinued - Phase-II for Alzheimer's disease in Canada, Japan, USA (IV), prior to October 2021 (Eli Lilly and Company pipeline, October 2021)